Role of active drug transporters in refractory multiple myeloma

Current Topics in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 218-224

  Tucci, Marco ^a   Quatraro, Cosima ^a   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

ABC transporters; MDR; Multiple myeloma; Sigma receptors

Indexed keywords

ABC TRANSPORTER; BORTEZOMIB; CASPASE; CYCLOSPORIN; CYTOTOXIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUNG RESISTANCE PROTEIN; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; PB 28; PENTAZOCINE; PIPERAZINE DERIVATIVE; PROTEIN P53; RECEPTOR SUBTYPE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; MOLECULAR MECHANICS; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; P-GLYCOPROTEIN;

EID: 63349091982     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609787521625     Document Type: Review

References (38)

1. Dalton, W.S. Mechanisms of drug resistance in hematologic malignancies. Semin. Hematol. 1997, 34, 3-8.
2. Pilarski, L. M.; Mant M. J.; Belch, A.R. Drug resistance in multiple myeloma: Novel therapeutic targets within the malignant clone. Leuk. Lymphoma 1999, 32, 199-210.
3. Cole, S.P.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.; Almquist, K.C.; Stewart, A.J.; Kurz, E.U.; Duncan, A. M.; Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
4. Sonneveld, P.; Durie, B.G.; Lokhorst, H.M.; Frutiger, Y.; Schoester, M.; Vela, E.E. Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br. J. Haematol. 1993, 83, 63-67.
5. Buda, G.; Maggini, V.; Galimberti, S.; Martino, A.; Giuliani, N.; Morabito, F.; Genestreti, G.; Iacopino, P.; Rizzoli, V.; Barale, R.; Rossi, A.M.; Petrini, M. MDR1 polymorphism influences the outcome of multiple myeloma patients. Br. J. Haematol. 2007, 137, 454-456.
6. Maggini, V.; Buda, G.; Martino, A.; Presciuttini, S.; Galimberti, S.; Orciuolo, E.; Barale, R.; Petrini, M.; Rossi, A.M. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet. Genomics 2008, 18, 383-388.
7. Schwarzenbach, H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med. Oncol. 2002, 19, 87-104.
8. Scheffer, G.L.; Schroeijers, A.B.; Izquierdo, M.A.; Wiemer, E.A.; Scheper, R.J. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr. Opin. Oncol. 2000, 12, 550-556.
9. Rimsza, L.M.; Campbell, K.; Dalton, W.S.; Salmon, S.; Willcox, G.; Grogan, T.M. The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. Leuk. Lymphoma 1999, 34, 315-324.
10. Dalton W.S.; Scheper. R.J. Lung resistance-related protein: Determining its role in multidrug resistance. J. Natl. Cancer Inst. 1999, 91, 1604-1605.
11. Ma, M.H.; Yang, H.H.; Parker, K.; Manyak, S.; Friedman, J.M.; Altamirano, C.; Wu, Z.Q.; Borad, M.J.; Frantzen, M.; Roussos, E.; Neeser, J.; Mikail, A.; Adams, J.; Sjak-Shie, N.; Vescio, R. A.; Berenson, J.R. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 2003, 9, 1136-1144.
12. Dalton, W.S.; Grogan, T.M.; Meltzer, P.S.; Scheper, R.J.; Durie, B. G.; Taylor, C.W.; Miller, T.P.; Salmon, S.E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of Pglycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 1989, 7, 415-424.
13. Dalton, W.S.; Grogan, T.M.; Rybski, J.A.; Scheper, R.J.; Richter, L.; Kailey, J.; Broxterman, H.J.; Pinedo, H.M.; Salmon, S.E. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation. Blood 1989, 73, 747-752.
14. Sonneveld, P.; Durie, B.G.; Lokhorst, H.M.; Marie, J.P.; Solbu, G.; Suciu, S.; Zittoun, R.; Löwenberg, B.; Nooter, K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 1992, 340, 255-259.
15. Avvisati, G. Bortezomib plus melphalan and prednisone for multiple myeloma. N. Engl. J. Med. 2008, 359, 2613.
16. Baumann, P.; Mandl-Weber, S.; Oduncu, F.; Schmidmaier, R. Alkylating agents induce activation of NFkB in multiple myeloma cells. Leuk. Res. 2008, 32, 1144-1147.
17. 1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol. Cancer Ther. 2006, 5, 1807-1816.
18. 1 antagonists in tumour cell lines. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370, 106-113.
19. 2 activity. J. Med. Chem. 2004, 47, 2308-2317.
20. Childs S.; Ling, V. The MDR superfamily of genes and its biological implications. Important Adv. Oncol. 1994, 21-36.
21. Beck, W.T. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat. Rev. 1990, 17 (Suppl A), 11-20.
22. Smit, J.J.; Schinkel, A.H.; Oude Elferink, R.P.; Groen, A.K.; Wagenaar, E.; van Deemter, L.; Mol, C.A.A.M.; Ottenhoff, R.; van der Lugt, N.M.T.; van Roon, M.A.; van der Valk, M.A.; Offerhaus, G.J.A.; Berns, A.J.M.; Borst, P. Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75, 451-462.
23. Sellers W.R.; Fisher, D.E. Apoptosis and cancer drug targeting. J. Clin. Invest. 1999, 104, 1655-1661.
24. Mercurio, F.; Murray, B.W.; Shevchenko, A.; Bennett, B.L.; Young, D.B.; Li, J.W.; Pascual, G.; Motiwala, A.; Zhu, H.; Mann, M.; Manning, A.M. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol. Cell Biol. 1999, 19, 1526-1538.
25. Li, Q.; Van Antwerp, D.; Mercurio, F.; Lee, K.F.; Verma, I.M. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999, 284, 321-325.
26. Grisham, M.B.; Palombella, V.J.; Elliott, P.J.; Conner, E.M.; Brand, S.; Wong, H.L.; Pien, C.; Mazzola, L.M.; Destree, A.; Parent, L.; Adams, J. Inhibition of NF-kappa B activation in vitro and in vivo: Role of 26S proteasome. Methods Enzymol. 1999, 300, 345-363.
27. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V.J.; Elliott, P.J.; Adams, J.; Anderson, K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61, 3071-3076.
28. Richardson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R.Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D.L.; Kauffman, M.; Adams, J.; Schenkein, D.P.; Anderson, K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
29. Naito, M.; Tsuruo, T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother. Pharmacol. 1997, 40 (Suppl), S20-24.
30. Alonso, G.; Phan, V.; Guillemain, I.; Saunier, M.; Legrand, A.; Anoal, M.; Maurice, T. Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system. Neuroscience 2000, 97, 155-170.
31. Su, T.P. Pharmacologic characterizations of sigma receptors. NIDA Res. Monogr. 1993, 133, 41-53.
32. Su, T.P. Delineating biochemical and functional properties of sigma receptors: Emerging concepts. Crit. Rev. Neurobiol. 1993, 7, 187-203.
33. 2 receptor protein expression and histopathologic grade in human bladder cancer. Cancer Lett. 2006, 237, 83-88.
34. Crawford, K.W.; Bowen, W.D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002, 62, 313-322.
35. Bowen, W.D. Sigma receptors: Recent advances and new clinical potentials. Pharm. Acta Helv. 2000, 74, 211-218.
36. 2 ligand activity in the isolated guinea-pig bladder. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 368, 106-112.
37. Silvestris, F.; Cafforio, P.; Calvani, N.; De Matteo, M.; Lombardi, L.; Dammacco, F. In vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leuk. Lymphoma 2006, 47, 1921-1931.
38. kip1 accumulation. J. Pharmacol. Exp. Ther. 2004, 311, 1105-1114.